Curis

Curis licensed IAP inhibitor GDC-0917 from Genentech

Wednesday, November 28, 2012 01:54 PM

Curis, a Lexington, Mass.-based drug development company focused on targeted small molecule drug candidates for cancer treatment, has licensed from San Francisco-based Genentech, a member of the Roche Group, exclusive worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins.

More... »


Phase II trial of Letermovir meets primary efficacy endpoints

Wednesday, February 15, 2012 03:54 PM

AiCuris, a clinical-stage biopharmaceutical company developing drugs against severe infectious diseases, released positive results from its placebo-controlled and dose-ranging phase II trial with Letermovir (AIC246).

More... »


AiCuris’ Letermovir receives Fast Track designation

Monday, August 29, 2011 12:58 PM

AiCuris announced today that the FDA has granted Fast Track designation for one of its lead drugs, AIC246, an inhibitor of the human cytomegalovirus (HCMV).

More... »

AiCuris presents results of AIC316 phase II

Tuesday, July 19, 2011 01:51 PM

Phase II results for AiCuris' novel non-nucleosidic herpes simplex virus (HSV) inhibitor AIC316 reveal safety and efficacy in persons with genital herpes.

More... »

Positive results for Curis phase II trial

Tuesday, March 29, 2011 12:46 PM

Curis, a drug development company focusing on next-generation targeted small molecule drug candidates for cancer treatment, announced a positive outcome from a pivotal phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly-owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.